Direct Answer
Vertex Pharmaceuticals reports revenue across 6 product and service lines in its fiscal 2025 Form 10-K. TRIKAFTAKAFTRIO is the largest, with $10.3 billion of revenue (86% of the total), followed by ALYFTREK at $838 million (7%). 63% of revenue came from the United States.
How Does Vertex Pharmaceuticals Make Money?
TRIKAFTAKAFTRIO supplies 86% of revenue, so Vertex Pharmaceuticals's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, CASGEVY grew fastest (+1058.0%) and TRIKAFTAKAFTRIO slowest (+0.7%), so the revenue mix tilts toward CASGEVY while that gap lasts.
| Product or service | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| TRIKAFTAKAFTRIO | $10.3 billion | $10.2 billion | 85.9% | 0.7% |
| ALYFTREK | $838 million | $0 | 7.0% | n/a |
| Manufactured Product Other | $820 million | $782 million | 6.8% | 4.9% |
| CASGEVY | $116 million | $10 million | 1.0% | 1058.0% |
| JOURNAVX | $60 million | $0 | 0.5% | n/a |
| Collaborative and Royalty | $31 million | $0 | 0.3% | n/a |
Where Does Vertex Pharmaceuticals's Revenue Come From?
Regions follow the definitions in the filing; most companies assign revenue by customer location.
| Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| United States | $7.5 billion | $6.7 billion | 62.9% | 12.9% |
| Europe | $3.5 billion | $3.5 billion | 28.8% | 0.2% |
| Other Countries Outsideof the United States and Europe | $992 million | $881 million | 8.3% | 12.6% |
What the Segment Figures Do Not Show
The rows above add up to 101% of Vertex Pharmaceuticals's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.
Where These Numbers Come From
Every figure on this page is a value Vertex Pharmaceuticals reported in the segment note and revenue disclosures of its Form 10-K filed February 13, 2026 (accession 0000875320-26-000056), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.
Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.
Frequently Asked Questions
What are Vertex Pharmaceuticals's main products and services?
In its fiscal 2025 Form 10-K, Vertex Pharmaceuticals reports revenue for TRIKAFTAKAFTRIO, ALYFTREK, Manufactured Product Other, CASGEVY, JOURNAVX and Collaborative and Royalty.
Which part of Vertex Pharmaceuticals brings in the most revenue?
TRIKAFTAKAFTRIO, with $10.3 billion of revenue in fiscal 2025, or 86% of the total.
How much of Vertex Pharmaceuticals's revenue comes from outside the United States?
37% in fiscal 2025, by the geographic breakdown Vertex Pharmaceuticals reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies.